Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study

Planned interim analysis from DENALI Part 2a shows differentiated response rate at higher dose with comparable safety

Apr. 9, 2026 at 12:03pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the intricate internal structures of a human ovary, conceptually representing the clinical focus on ovarian cancer.Zentalis' investigational WEE1 inhibitor azenosertib aims to offer a targeted, biomarker-driven treatment approach for ovarian cancer patients.San Diego Today

Zentalis Pharmaceuticals announced the selection of a 400mg once daily on a 5-days-on, 2-days-off schedule as the optimal monotherapy dose of its investigational WEE1 inhibitor azenosertib for the potentially pivotal DENALI Phase 2 and confirmatory ASPENOVA Phase 3 trials in Cyclin E1-positive platinum-resistant ovarian cancer. The decision was based on a planned interim analysis from DENALI Part 2a that showed a clearly differentiated response rate at the 400mg dose compared to 300mg, with comparable safety profiles between the two dose groups.

Why it matters

The selection of the pivotal dose is a key milestone that supports Zentalis' registration-intended development path for azenosertib. As an oral monotherapy, azenosertib has the potential to offer Cyclin E1-positive platinum-resistant ovarian cancer patients a more convenient treatment option compared to current standard-of-care intravenous chemotherapies, if approved.

The details

In the DENALI Part 2a interim analysis, the 400mg QD 5:2 dose showed a meaningful and clearly differentiated response rate over the 300mg QD 5:2 dose, with comparable safety profiles across the two dose groups. Zentalis also reported improvements in several key safety measures, such as a lower discontinuation rate due to adverse events compared to the earlier DENALI Part 1b study.

  • The DENALI Part 2 topline readout is expected by the end of 2026.
  • Enrollment in the new DENALI Part 2c cohort, which will broaden the study population, is planned to initiate in Q2 2026.
  • The confirmatory ASPENOVA Phase 3 trial is expected to initiate in Q2 2026.

The players

Zentalis Pharmaceuticals, Inc.

A clinical oncology innovator advancing late-stage development of its investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer.

Julie Eastland

Chief Executive Officer of Zentalis Pharmaceuticals.

Ingmar Bruns, M.D.

Chief Medical Officer of Zentalis Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“Selecting the pivotal monotherapy dose for azenosertib is a key inflection point that supports our registration-intended path. Beyond executing on DENALI and ASPENOVA, we are initiating launch preparedness by adding commercial capabilities to our organization, scaling manufacturing capacity, and advancing companion diagnostic development.”

— Julie Eastland, Chief Executive Officer

“The emerging DENALI Part 2a data from the planned interim analysis provide a favorable benefit-risk profile at the 400mg QD 5:2 dose over 300mg QD 5:2. A meaningful, differentiated response rate with the selected dose and comparable safety profiles across both dose groups were observed in this interim analysis.”

— Ingmar Bruns, M.D., Chief Medical Officer

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.